Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction

J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e430-e431. doi: 10.1111/jdv.16379. Epub 2020 May 6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adalimumab
  • Hidradenitis Suppurativa* / drug therapy
  • Humans
  • Immunologic Factors
  • Risk Reduction Behavior
  • Tumor Necrosis Factor-alpha*

Substances

  • Immunologic Factors
  • Tumor Necrosis Factor-alpha
  • Adalimumab